NCT06383780View on ClinicalTrials.gov

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 15, 2027

Study Completion Date

May 15, 2029

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

GP combined with Tislelizumab

Gemcitabine combined with cisplatin regimen combined with Tislelizumab

DRUG

TPC combined with Tislelizumab

cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab

Trial Locations (1)

510060

RECRUITING

SunYat-senU, Guangzhou

All Listed Sponsors
lead

XIANG YANQUN

OTHER